Stryker,ein starkes Unternehmen aus dem medizin

Sektor.
Stryker Corp. ist ein Anbieter von medizinischen und chirurgischen Produkten. Das Leistungsspektrum umfasst orthopädische Implantate, Trauma-Systeme, das für den Knochenwachstum verantwortliche osteogene Protein-1 (OP-1), verschiedene chirurgische Instrumente, Endoskopie-Systeme sowie verschiedenes Zubehör und Verbrauchsmaterial für die Versorgung von Patienten.
GuV in Mio. US Dollar nach USGAAP
      2002    2003    2004    2005    2006    2007
Umsatz 3.011,6 3.625,3 4.262,3 4.871,5 5.405,6 6.000,5
Bruttoergebnis vom Umsatz 1.900,4   2.312,9   2.752,2   3.157,6   3.556,9   4.135,3
Operatives Ergebnis (EBIT) 547,5   671,3   720,4   998,8   1.074,3   1.307,3
Ergebnis vor Steuer (EBT) 506,7   652,5   717,0   1.003,3   1.103,8   1.370,1
Jahresüberschuss/-fehlbetrag 345,6   453,5   465,7   675,2   777,7   1.017,4
 

(RTTNews) -  Thursday, after the bell, medical technology company Stryker Corp. (SYK: News, Chart, Quote ) reported an increase in its earnings for the second quarter, helped by higher Orthopaedic Implant and MedSurg Equipment sales. Further, the company provided guidance for the full-year 2008.

For the second quarter, net earnings increased to $306 million or $0.73 per share from $269.1 million or $0.65 per share in the same quarter last year. Analysts polled by First Call/Thomson Financial expected profit of $0.73 per share for the quarter.

Net sales rose 17.0% to $1.713 billion from $1.464 billion a year ago, and topped the consensus estimate of $1.68 billion. Orthopaedic Implant sales increased 14.5% to $1.02 billion, while MedSurg Equipment sales increased 20.8% to $696.4 million.

For the six-month period, net income rose to $596.3 million or $1.43 per share from $512.6 million or $1.23 per share last year. Sales for the period grew to $3.35 billion from $2.9 billion a year ago.

The company expects fiscal 2008 earnings per share to be around $2.88. Net sales are estimated to grow in the range of 11% to 13%. Analysts expect earnings of $2.88 per share for the year.

Stryker closed Thursday's regular trading session at $68.41, down $0.08 or 0.12%. In the after-hours trading, the company's shares traded at $66.99, down $1.42 or 2.08%.

by RTT Staff Writer

For comments and feedback: contact editorial@rttnews.com
 

It's hard to complain about a company that posts double-digit sales growth for 30 consecutive quarters, but investors are finding a way today after Stryker (NYSE: SYK) reported earnings Thursday afternoon.

The company operates in two segments. The first, orthopedic implants, reported 15% year-over-year growth, with three of its five product franchises growing by more than 20%. What weighed this segment down was its hip replacement business, which grew by just 7% because an earlier recall of its Trident hip product is still affecting sales. However, Stryker is again supplying the Trident and is working to restore market share that it lost to Johnson & Johnson (NYSE: JNJ).

The other half of Stryker's business, medsurg equipment, posted nice 21% year-over-year growth in second-quarter sales, thanks in large part to healthy international growth of 37%, which is reduced to 25% after correcting for currency exchange. Back at home, the segment that sells medical equipment to hospitals posted year-over-year growth of 16%.

All isn't perfect with Stryker, however. The company is dealing with three Food and Drug Administration warning letters that deal with quality-control issues and FDA inspections at two manufacturing plants. Stryker said it will spend $50 million per year over the next few years to deal with the problem.

There are two likely reasons for today's decline. First, investors have come to expect the growth, so numbers like the ones above are no longer as exciting. Even though the company beat estimates by a penny, in today's market, that isn't enough. Second, the FDA issue could still be weighing on the company.

It'll be interesting to see what happens when fellow medical implant companies Zimmer (NYSE: ZMH) and Smith & Nephew (NYSE: SNN) report earnings in the coming weeks. Both sport P/Es that are in line with or higher than Stryker's P/E, suggesting that investors are expecting more of the same double-digit growth from the rest of the industry.

 

Device makers lifted on Medicare plan
Cuts shallower than expected, giving aid to cardio group
By Russ Britt, MarketWatch
Last Update: 12:32 PM ET Aug 2, 2006


LOS ANGELES (MarketWatch) -- Medical device makers got a boost Wednesday as expected reductions in reimbursements from the Centers for Medicare and Medicaid Services won't take as much of a bite as had been anticipated.
Shares of companies such as Medtronic, St. Jude Medical and Boston Scientific traded up more than 2%. Fee schedules for such devices as stents -- expected to be cut by more than 30% in some cases -- were reduced by only a few percentage points.
The news came as a welcome relief for many device makers' stocks, which have experienced volatility in recent weeks and months in anticipation of the ruling. Deutsche Bank analyst Tao Levy said in a note to clients that investors should see less volatility in the stocks.
"As a result, and given that we are now more positive on the reimbursement outlook for the med-tech sector, we would expect a slight multiple expansion," Levy wrote.
The Centers for Medicare and Medicaid Services, or CMS, had proposed cuts of up to 34% at one time for drug-eluting stent reimbursement, but the agency's now pared that back to a little more than 2%. Implantable cardio-defibrillators had been penciled in for more than 22% in reductions, but now they will be cut between 2% and 3%.
And instead of cutting payments for pacemakers, heart valves and joint replacements, CMS will instead raise reimbursement rates.
Other stocks that gained on the news included Alphatec Holdings Inc. , Biomet Inc. , Stereotaxis , Stryker Corp. and Zimmer Holdings Inc.
Analysts cautioned, though, that there may be roadblocks for these and other companies in the future. While CMS may not cut reimbursements as much as was anticipated, there could be other demands that the agency makes.
"One of CMS's focuses has been increased pricing transparency on the hospital side, but now medical devices also seem to be on the agenda," UBS Investment Research's Kenneth Weakley wrote in a note to clients.
And Citigroup's Matthew Dodds said today's rally may not last, as many expected that the proposed CMS cuts never would see the light of day.
"From a fundamental standpoint, the aforementioned changes are not going to impact our market forecasts since we did not expect the initial cuts to hold and never lowered our estimates once they came out," Dodds said in a note to clients. "Our sense is that most of our competitors did not lower estimates either and hence are not apt to increase them today."
Russ Britt is the Los Angeles bureau chief for MarketWatch.

 

ich halte mehr von medtronic auf dem Gebiet der medizinischen  Produkte, weil im Punkte doppellter Herzschritmacher mehr potenzial drinne steckt

Analysis
The EV/EBITDA ratio is a relevant ratio for financial analysis. Stryker Corp. shows a EV/EBITDA ratio of 11.82 for the next 12 months, which is higher than the median of its peer group: 11.11 according to this financial analysis Stryker Corp. valuation is above its peer group's.
this ratio is higher than the average of its sector (Medical Equipment) 9.89 according to this financial analysis Stryker Corp. valuation is above its sector.

EV/EBITDA ratio of Stryker Corp. (US8636671013 - SYK) and its peer group for financial analysis
Stryker Corp.Peer group: Ratios based on Fri Aug 15.
Stryker Corp. Peer group
Enterprise Value(USD '000) EV/EBITDA Relevance Score
2009 next 12 mth
Stryker Corp. 25 185 550 11.26 11.82  
Zimmer Holdings 15 985 713 9.37 9.73 100%
Smith Nephew 11 687 671 9.72 10.23 87%
Medtronic 66 211 275 10.64 11.38 83%
STERIS Corp. 2 360 530 N/A N/A 79%
Synthes 15 915 274 10.80 11.27 74%
Hill-Rom Holdings Inc. 2 041 049 7.67 7.81 65%
Stryker Corp. Benchmark
 EV/EBITDA
next 12 mth
Company Stryker Corp. 11.82
Peer group Stryker Corp. excluded 11.11
Stryker Corp. included 11.23
Sector Medical Equipment 9.89
S&P 500  7.72
DJ STOXX 600  6.23
Country USA 7.86

Get full financial analysis in Corporatefocus Screener now:Corporatefocus Screener - the product suited for all valuation specialist and analysts. It gives direct access to fundamentals and market data. Every time a company is selected, Snapshot is the default page, showing an overview of key data items.

Get a complete financial analysis for Stryker Corp. Register now for a 3-Day Free Trial of Corporatefocus. Through Corporatefocus, Infinancials delivers financial analysis tools on more than 70,000 companies world-wide.

Free Trial Subscribe Now
Register now for a
3-day Free Trial of Corporatefocus Buy Corporatefocus online
Start using it instantly
About Us - Contact Us - Disclaimer - Privacy Statement
Copyright © 2008 Infinancials  

aufmerksam auf einen starken Wert. Stryker kann mit beeinduckenden Zahlen sowohl in der Vergangenheit als auch in der Gegenwart beeindrucken und ist der Marktführer in seinem Segment,nebenbei hat das Unternehmen noch ein Aktienrückkaufprogramm am laufen.
schaut euch die Performance an und dann entscheidet euch.  

in dieser Woche immer über 1 Mio gehandelte Stücke in den USA das spricht für sich, klarere Outperformer der den Dow weit hinter sich läßt. Nächstes Ziel sind die 70 $ .  

   
Artikel bookmarken bei:     FDA-Zulassung für neuartiges Hüft-Implantat von StrykerDatum 25.08.2006 - Uhrzeit 19:01 (© BörseGo AG 2007, Autor: , © GodmodeTrader - http://www.godmode-trader.de/)
WKN: 864952 | ISIN: US8636671013 | Intradaykurs:  
Stryker bekommen die Zulassung von der FDA für ein neuartiges Hüftimplantat. Die Technologie basiert auf einer speziellen Fertigung durch Ion-Behandlung und ermöglicht eine Integration des Implantats mit geringer Reibung im Knochen. Stryker will das Implantat ab September anbieten.



 

 

und wenn es heute über 68,50 geht ist der Weg frei bis 76 $.  

da werden in den Staaten seit Wochen weit über 1 Mio Stück täglich gehandelt und wir haben einen von fundamentalen Daten gestützten  ansteigenden Kurs und in Deutschland gehen gerade mal 1000 Stück am Tag über den Tresen.
Das verstehe wer will, anscheinend sind Marktführer hier keine Kaufkandidaten und Wertsteigerungen über 10% den Leuten hier zu wenig.  

die 47,50 sind das drei Monatshoch und dann haben wir die 50 euro in Aussicht und das dritte und vierte Quartal sind traditionell stärker.
Weiter viel Erfolg, p.s in NY sind vor der Eröffnung die ersten 100000 Aktien schon gehandelt worden  

Es ist schon erstaunlich, dass ein Unternehmen mit einer Mrd. Gewinn hier seit zwei Jahren gar nicht diskutiert wird. Medizintechnik ist für mich eine weltweite Zukunftbranche, die mit Sicherheit stetig wachsen wird, denn die Kranken werden nicht weniger.